Xultophy(IDegLira) ,a combination of insulin degludec(Tresibar) and liraglutide(Victoza) is approved by European Commission for marketing in EU

Xultophy(IDegLira) ,a combination of insulin degludec(Tresibar) and liraglutide(Victoza) is approved by European Commission for marketing in EU states .Xultophy  once daily injection is indicated for treatment of adults with type 2 dieabetes mellitus  . This drug improves glycaemic control in combination with  oral glucose -lowering  products.
when compared with insulin degludec ,Xultophy showed reduction in HbA1C of 1.9% with mean weight loss of 2.7 kg  and also a low rate of hypoglycaemia.
Novo Nordisk, the developer of Xultophy(IDegLira) has submitted marketing authorisation with EU on may 31st of '13 and got approval in Switzerland on 12 september  '14
Chemistry:
Insulin degludec:
Structure:Modified insulin with 1 single amino acid delted in comparison to human insulin and  cojugated to hexadecanedioic acid via gamma-L-glutamyl spacer at amino acid Lysine at B29 position.
IUPAC name:B29N(epsilon)-omega-carboxypentadecanoyl-gamma-L-glutamyl desB30 human insulin
Mechanisam of Action(MOA): It forms multi hexamers in subcutaneous tissues by addition of hexadecanedioic acid to lysine at the B29 position .This results in in formation of a subcutaneous depot that results in slow insulin release in to systemic circulation.
Duration of action: It is  ultra-long acting with duration which lasts up to 40 hours .
Liraglutide:
Molecular Formula:C17H265N43051
Molecular Weight:3751.202
MOA of Liraglutide:
1-Liraglutide increases intracellular cyclic AMP[cAMP]  which leads to insulin release in presence of elevated glucose concentrations.This secretion subsides a s glucose concentrations decrease and approach euglycemia.
2-decreasing glucagon secretion in glucose dependent manner
3-delaying gastric emptying.

Saxenda (Liraglutide) of Novo Nordisk received 14-1 positive vote for approval from EMDAC of US FDA.

Saxenda (Liraglutide) of Novo Nordisk received 14-1 positive vote for approval from EMDAC ( Endocrinologic an Metabolic Drugs Advisory  Committee) of US FDA.
The panel members were asked to discuss whether Novo Nordisk has provided enough data to establish the safety and efficacy profile of Saxenda(Liraglutide)  for chronic weight management based on the NDA data submitted.
Overall benefit-risk assessment of Saxenda(Liraglutide) got 14-1 votes from the panel members for weight management in patients with BMI 30kg/m2 or greater.
       NDA for Saxenda(Liraglutide) was submitted on october 2013 with US FDA. The data submitted for NDA included phase 3 SCALET  clinical trial in which 5000 people with obesity were involved.

Isocratic vs Gradient Mode

Isocratic vs Gradient

In isocratic mode a constant single solvent or constant mixture of solvents are used  in analysis where as in gradient mode the composition of solvents is changed constantly while performing analysis for enhancing the separation efficiency i.e to get faster elution of sample from mixture.

Sink Condition

Sink Condition is the  medium volume that is three times or more greater than the volume required to form a saturated solution. It is used in Dissolution studies